Want to see LPCN full AI Analyst Report?
Lipocine (LPCN) Stock Statistics & Valuation Metrics
Total Valuation
Lipocine has a market cap or net worth of $17.39M. The enterprise value is -$3.32M.
- Market Cap
- $17.39M
- Enterprise Value
- -$3.32M
Share Statistics
Lipocine has 11,073,439 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 11,073,439
- Owned by Insiders
- 3.77%
- Owned by Institutions
- 20.98%
Financial Efficiency
Lipocine’s return on equity (ROE) is -0.67 and return on invested capital (ROIC) is -69.48%.
- Return on Equity (ROE)
- -0.67
- Return on Assets (ROA)
- -0.57
- Return on Invested Capital (ROIC)
- -69.48%
- Return on Capital Employed (ROCE)
- -0.72
- Revenue Per Employee
- 141.19K
- Profits Per Employee
- -687.68K
- Employee Count
- 14
- Asset Turnover
- 0.12
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Lipocine is -1.15. Lipocine’s PEG ratio is 0.02.
- PE Ratio
- -1.15
- PS Ratio
- 3.46
- PB Ratio
- 0.61
- Price to FCF
- -4.43
- Price to Operating Cash Flow
- -4.43
- PEG Ratio
- 0.02
Income Statement
In the last 12 months, Lipocine had revenue of 1.98M and earned -9.63M in profits. Earnings per share was -1.77.
- Revenue
- 1.98M
- Gross Profit
- -6.61M
- Operating Income
- -10.37M
- Pretax Income
- -9.63M
- Net Income
- -9.63M
- EBITDA
- -9.57M
- Earnings Per Share (EPS)
- -1.77
Cash Flow
In the last 12 months, operating cash flow was -2.92M and capital expenditures 0, giving a free cash flow of -2.92M billion.
- Operating Cash Flow
- -2.92M
- Free Cash Flow
- -2.92M
- Free Cash Flow per Share
- -0.35
Dividends & Yields
Lipocine pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -22.56%
- Earnings Yield
- -72.09%
Stock Price Statistics
- Beta
- 0.25
- 52-Week Price Change
- -40.53%
- 50-Day Moving Average
- 1.93
- 200-Day Moving Average
- 3.56
- Relative Strength Index (RSI)
- 43.83
- Average Volume (3m)
- 1.82M
Important Dates
Lipocine upcoming earnings date is ―, Before Open (Confirmed).
- Last Earnings Date
- Aug 04, 2026
- Next Earnings Date
- ―
- Ex-Dividend Date
- ―
Financial Position
Lipocine as a current ratio of 6.68, with Debt / Equity ratio of 3.11%
- Current Ratio
- 6.68
- Quick Ratio
- 6.68
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.50
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Lipocine has paid 200 in taxes.
- Income Tax
- 200
- Effective Tax Rate
- -0.00
Enterprise Valuation
Lipocine EV to EBITDA ratio is -1.20, with an EV/FCF ratio of -3.54.
- EV to Sales
- 2.76
- EV to EBITDA
- -1.20
- EV to Free Cash Flow
- -3.54
- EV to Operating Cash Flow
- -3.54
Balance Sheet
Lipocine has $21.46M in cash and marketable securities with $0.00 in debt, giving a net cash position of $21.46M billion.
- Cash & Marketable Securities
- $21.46M
- Total Debt
- $0.00
- Net Cash
- $21.46M
- Net Cash Per Share
- $1.94
- Tangible Book Value Per Share
- $2.57
Margins
Gross margin is 38.05%, with operating margin of -245.86%, and net profit margin of -249.16%.
- Gross Margin
- 38.05%
- Operating Margin
- -245.86%
- Pretax Margin
- -249.15%
- Net Profit Margin
- -249.16%
- EBITDA Margin
- -230.17%
- EBIT Margin
- -231.36%
Analyst Forecast
The average price target for Lipocine is $4.00, which is 11.43% higher than the current price. The consensus rating is Neutral
- Price Target
- $4.00
- Price Target Upside
- 154.78% Upside
- Analyst Consensus
- Neutral
- Analyst Count
- 1
- Revenue Growth Forecast
- -13.37%
- EPS Growth Forecast
- -33.44%
Scores
- Smart Score
- ―
- AI Score
- 45
